IL1B and COVID-19: This unique experience on a homogeneous population cohort now provides an unprecedented occasion to address clinical and serological variables associated with COVID-19 response to anti-cytokine therapies, and to identify a “window of therapeutic opportunity” for maximizing the efficacy of IL-1 and IL-6 blockade in these patients.